PumasAI launches enterprise AI service for pharma productivity gains

By AI, Created 2:10 PM UTC, May 21, 2026, /AGP/ – PumasAI introduced Catalyst, an enterprise AI transformation service aimed at pharmaceutical and biotech teams on May 21, 2026. The company says the offering can help modernize pharmacometrics workflows, cut manual work and deliver up to 50% productivity growth within 12 months.

Why it matters: - Catalyst is aimed at a core bottleneck in drug development: slow, manual clinical pharmacology and pharmacometrics work. - PumasAI says the service can help teams modernize workflows, free scientists from repetitive tasks and move therapies toward market faster. - The company is positioning AI adoption as an operational lever for regulated scientific teams, not just a software upgrade.

What happened: - PumasAI announced Catalyst, a new enterprise AI transformation service for pharmaceutical and biotech organizations. - The launch took place on May 21, 2026, in Dover, Delaware. - PumasAI says Catalyst is designed to deliver up to 50% productivity growth within 12 months. - The service is built around smarter AI adoption, workflow modernization and stronger operational alignment.

The details: - PumasAI says its own internal consulting teams used AI-powered workflows and automation before the launch. - The company says those changes reduced repetitive work, accelerated modeling workflows and increased capacity for higher-value scientific decisions. - Catalyst is intended to help teams modernize pharmacometrics workflows through Pumas, PumasAide and enterprise-approved AI tools. - PumasAI says the service can reduce time spent on repetitive workflow tasks. - PumasAI says teams can explore about twice as many model variants during each analysis. - PumasAI says Catalyst can speed the path from raw data to regulatory-ready reports. - Dr. Vijay Ivaturi, co-founder and CEO of PumasAI, said the company saw a 50% productivity increase internally and wants other organizations to reach similar gains. - Catalyst uses a three-phase engagement model: Discover, Transform and Accelerate. - Discover includes workflow mapping, tool-chain audits, infrastructure reviews, team assessments and productivity benchmarking. - Transform covers migration of model libraries into Pumas, deployment of PumasAide, replacement of manual workflows with automated pipelines and validation frameworks aligned with internal requirements. - PumasAI says organizations can target a 25% to 30% productivity improvement during the Transform phase. - Accelerate includes team certification, parallel-run transitions for critical analyses, targeted optimization and long-term sustainability planning. - PumasAide is designed to assist with scientific model code generation, data preparation, diagnostics, sensitivity analyses, regulatory documentation and end-to-end workflow orchestration. - PumasAI says every output is reviewed and approved by clinical pharmacology and pharmacometrics scientists.

Between the lines: - The launch reflects a broader push to apply AI where regulatory pressure and scientific complexity have made productivity gains difficult. - PumasAI is framing human review as a guardrail, which is important for adoption in validated, high-stakes environments. - The 50% productivity claim is central to the pitch, but the more immediate value may be the phased rollout and measurable intermediate gains.

What’s next: - PumasAI says organizations can use Catalyst to build toward and maintain a 50% productivity goal over time. - The company is also directing prospects to its webinar on in-silico clinical trials with NLME models. - More information is available in PumasAI’s Catalyst overview. - Registration is open for the in-silico clinical trials webinar.

The bottom line: - PumasAI is betting that AI-enabled workflow redesign can become a measurable operating model for pharma teams, not just a productivity tool.